The Harmony Healthcare Fund is an open-end equity fund looking for Chinese healthcare companies that are undervalued in overseas securities markets and have sustainable high growth potential. Through strategic consulting and resource injection, we help companies quickly create value and grow into leaders in the medical subsectors. 

Harmony Healthcare Fund was awarded by AsiaHedge in October 2018 as the World's Best Small Fund.

Investment cases

Sinopharma (01093.HK): A classic case of transformation from compound producer to innovative drug leader

Essex Pharma (01061.HK): A biotech leader in ophthalmology, dermatology, and surgical treatments